Alendronate Sodium Salt Trihydrate

This product is for research use only. Do not administer it to human.

Osteoclastic Inhibitors: Research for Bone Metabolism
 

• Alendronate Sodium Salt Trihydrate (Wako Cat. #012-22661; #018-22663)
• Risedronate Sodium Salt n-Hydrate (Wako Cat. #189-02461; #185-02463)

Bone tissue is being remodeled by continuous deossification and ossification. The number of patients with osteoporosis caused by imbalance in the bone metabolism is increasing with the transition to an aging society.
This product is a bisphosphonate compound that is selectively distributed in the calcified bone surface to which the osteoclasts are attached. It is released under an acid environment created by the osteoclasts, taken in the cells, and inhibits the bone resorption activity. The inhibition of the bone resorption is considered to be caused by apoptosis induction effect of the osteoclasts and direct suppression of bone resorption of the osteoclasts.
 

Related Product:
TRAP/ALP Stain Kit (Wako Cat. #294-67001) - for enzyme activity staining of tartrate-resistant acid phosphatase -